top of page

FDA Approved Targeted Therapies 

Untitled.jpg

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression, and spread of cancer.

​

Each personalized gene profile provides information on current FDA-approved treatment options proven effective for the tumor DNA mutations identified.

​

Sources: cancer.gov and fda.gov

ALK Fusions

Alectinib
Brigatinib
Ceritinib
Crizotinib
Lorlatinib

ATM (prostate cancer)

Olaparib

BARD1 (prostate cancer)

Olarparib

BRAF

Dabrafenib plus Trametinib
Encorafenib plus Binimetinib
Vemurafenib plus Cobimetinb

BRCA1/BRCA2

Niraparib
Olarparib
Rucaparib
Talazoparib

CDK12 (prostate cancer)

Olarparib

CHEK1 (prostate cancer)

Olarparib

CHEK2 (prostate cancer)

Olarparib

EGFR

Afatinib
Dacomitinib
Erlotinib
Gefitinib
Osimertinib

EGFR exon 20

Amivantamab
Mobocertinib

ERBB2 Gene Amplification

Ado-Trastuzumab Emtansine
Lapatinib
Margetuximab
Neratinib
Pertuzumab
Trastuzumab
Trastuzumab Deruxtecan

EZH2

Tazemetostat

FGFR2/FGFR3 Fusions

Erdafitinib
Infigratinib
Pemigatinib

IDH1

Ivosidenib

KIT

Imatinib
Regorafenib
Ripretinib
Sunitinib

KRAS G12C

Sotorasib

MET

Cabozantinib
Capmatinib
Crizotinib
Tepotinib

MSI-H

Immune Checkpoint Inhibitor

NF1

Selumetinib

NTRK Fusions

Entrectinib
Larotrectinib

PALB2 (prostate cancer)

Olarparib

PD-L1

Immune Checkpoint Inhibitor

PDGFRA

Avapritinib
Imatinib

PIK3CA

Alpelisib

RET Fusions/Mutations

Pralsetinib
Selpercatinib

ROS1 Fusions

Crizotinib
Entrectinib

SMARCB1

Tazemetostat

bottom of page